Singapore Clinical Trial: CO45042: A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib Plus Pembrolizumab Versus Pembrolizumab And Pemetrexed And Carboplatin or Cisplatin in Patients with Previously Untreated, KRAS G12C-Mutated, Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'CO45042: A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib P... Read More

Singapore Clinical Trial: A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durva... Read More

Singapore Clinical Trial: A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durva... Read More

Singapore Clinical Trial: TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label... Read More

Singapore Clinical Trial: A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety,... Read More

Singapore Clinical Trial: Role of glucagon-like peptide 1 receptor Agonist (GLP1 RA) Dulaglutide on cerebral hemodynamics In patients with severe and symptomAtic steNosis of inTracranial internal carotid artery or middle cerebral artery with impaired cerebral vasodilatory reserve- an open-label randomised clinical trial (RADIANT)

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'Role of glucagon-like peptide 1 receptor Agonist (GLP1 RA) Dulaglutide on cerebral hemodynamics In p... Read More

Singapore Clinical Trial: A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as the safety, tolerability, and pharmacokinetics of oral PKN605 in participants with atrial fibrillation

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the effica... Read More

Singapore Clinical Trial: A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adi... Read More

Viet Nam welcomes 8.8 million foreign visitors in January-April period

Hanoi, May 4 -- With the above figure, the tourism sector has already achieved 35 percent of its preset goal of attracting 25 million international visitors in 2026. In the reviewed period, the top 1... Read More

NNPC signs MoU with Chinese firms to revive Warri, Port Harcourt refineries

Nigeria, May 4 -- The Nigerian National Petroleum Company Limited (NNPCL) has announced that it signed a Memorandum of Understanding (MoU) with two Chinese companies to support the completion, operati... Read More

• ««
• «
• 18565
• 18566
• 18567
• 18568
• 18569
• 18570
• 18571
• 18572
• 18573
• 18574
• »
• »»